Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2022 08:00 ET | Source: Immix Biopharma, Inc.

Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

16th patient dosed with IMX-110 to dateThis is the second patient dosed with IMX-110 in December 2022Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical...
December 19, 2022 08:00 ET | Source: Immix Biopharma, Inc.

ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors

Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid TumorsIMX-110 + Tislelizumab...
December 14, 2022 08:00 ET | Source: Immix Biopharma, Inc.

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff...
December 13, 2022 08:00 ET | Source: Immix Biopharma, Inc.

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans...
December 12, 2022 08:00 ET | Source: Immix Biopharma, Inc.

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics...
November 11, 2022 08:00 ET | Source: Immix Biopharma, Inc.

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”)While their future value is uncertain, PRVs are transferable to other...
October 25, 2022 08:00 ET | Source: Immix Biopharma, Inc.

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix...
October 18, 2022 08:00 ET | Source: Immix Biopharma, Inc.

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

California Soft Tissue Sarcoma Site to lead expanded clinical site consortiumHistorically, high-enrolling lead site has enrolled 2-3 patients per monthClinical trial data expected to be released on a...
September 07, 2022 12:05 ET | Source: Immix Biopharma, Inc.

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 +...
May 20, 2022 08:47 ET | Source: Immix Biopharma, Inc.

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft...